Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.33
+0.49002.75%
Volume:15.20K
Turnover:278.31K
Market Cap:108.15M
PE:- -
High:18.40
Open:18.25
Low:18.23
Close:17.84
52wk High:21.50
52wk Low:14.38
Shares:5.90M
Float Shares:5.90M
Volume Ratio:1.14
T/O Rate:0.26%
Dividend:0.71
Dividend Rate:3.90%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Innovent Biologics' H1 Profit Jumps 50%

MT Newswires Live
·
Aug 25

Innovent Biologics - Re-Designates Ronald Hao Xi Ede as Non-Executive Director Effective September 1, 2026

THOMSON REUTERS
·
Aug 25

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Aug 25

Innovent Announces 2026 Interim Results and Business Updates

THOMSON REUTERS
·
Aug 25

INNOVENT BIO Reports First-Half Profit of RMB 1.253 Billion, Up 50.2% Year-on-Year

Stock News
·
Aug 25

Innovent Biologics - Potential to Maintain Rapid Revenue Growth to RMB35 Bln to RMB40 Bln Total Revenue by 2030

THOMSON REUTERS
·
Aug 25

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Aug 25

Innovent Biologics H1 FY26 IFRS Profit Climbs 50.2% to RMB 1.25 Billion; Revenue Rises 44.8% to RMB 8.62 Billion

Reuters
·
Aug 25

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Aug 25

Innovent Biologics H1 Revenue RMB 8,617.8 Million

THOMSON REUTERS
·
Aug 25

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

Reuters
·
Aug 25

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS
·
Aug 25

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

Dow Jones
·
Aug 25

HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results

Reuters
·
Aug 25

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Stock News
·
Aug 25

Transcenta Holding Announces Extraordinary General Meeting

Reuters
·
Aug 25

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

Reuters
·
Aug 24

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Reuters
·
Aug 24

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live
·
Aug 24

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 24